Early filing for melanoma drug adds to Merck's renewed R&D hopes
This article was originally published in Scrip
After being criticized for much of the past year for having a stagnant research and development pipeline, investors on 13 January breathed new life into Merck's shares, which rose as high as 7.1% in morning trading, on the news the FDA had given the firm's experimental cardiovascular drug vorapaxar a positive review and the company had started the process of submitting a rolling biologics license application (BLA) for its investigational anti-PD-1 immunotherapy MK-3475, also known as lambrolizumab, in advanced melanoma.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.